UK breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.0% during the forecast period. Increasing the incidence of breast cancer coupled with governemnt intitives are the major factors that contributing to the growth of the market. According to Cancer Research UK, incidence rates for breast cancer are projected to rise by 2% in the UK between 2014 and 2035, to 210 cases per 100,000 females by 2035. The awareness programs and research funding on breast cancer also enable the growth of the market. In 2015 the Public Health England (PHE) launched the ‘Be Clear on Cancer’ campaign for the purpose of women aged 70 and over to drive awareness of the risk of breast cancer. Cancer Research UK funded about $38 million for breast cancer research in 2017. This funding enabled to create a network of research at 90 institutions in more than 40 states in the UK.
UK breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.
The companies which are contributing to the growth of UK breast cancer diagnostics and therapeutics market include, Agendia NV, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the UK breast cancer diagnostics and therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. UK Breast Cancer Diagnostics and Therapeutics Market by Cancer Type
5.1.1. Ductal Carcinoma In-Situ (DCIS)
5.1.2. Invasive Ductal Carcinoma (IDC)
5.1.3. Triple Negative Breast Cancer (TNBC)
5.1.4. Inflammatory Breast Cancer
5.1.5. Others (Invasive lobular carcinoma)
5.2. UK Breast Cancer Diagnostics and Therapeutics Market by Diagnostics
5.2.1. Mammography
5.2.2. Biopsy
5.2.3. PET/CET
5.2.4. Ultrasound
5.2.5. Others (MRI)
5.3. UK Breast Cancer Diagnostics and Therapeutics Market by Therapeutics
5.3.1. Chemotherapy
5.3.2. Hormone Therapy
5.3.3. Targeted Therapy
5.3.4. Others (Radiation Therapy, Surgery)
6. Company Profiles
6.1. Agendia NV
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. GlaxoSmithKline PLC
6.5. Mylan NV
6.6. Merck & Co., Inc.
6.7. Novartis International AG
6.8. F. Hoffmann-La Roche AG
6.9. Sanofi S.A.
6.10. Siemens Healthcare GmbH
1. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
2. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2018-2025 ($ MILLION)
3. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)
1. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)
2. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY DIAGNOSTICS, 2018 VS 2025 (%)
3. UK BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)